Drug Toxicity
Research News and Information

Sunday, November 22, 2009

Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry.

29 Nov 2009 AIMS: To examine the efficacy and safety of pegfilgrastim in patients with congenital neutropenia (CN). METHODS: Seventeen patients enrolled in the French Severe CN Register received pegfilgrastim. RESULTS: Median age at pegfilgrastim introduction ... Read more...

Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.

6 Oct 2009 Protease activated receptors (PARs) or thrombin receptors constitute a class of G-protein-coupled receptors (GPCRs) implicated in the activation of many physiological mechanisms. Thus, thrombin activates many cell types such as vascular smooth ... Read more...

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

6 Oct 2009 The potent and selective 5-lipoxygenase-activating protein leukotriene synthesis inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (11j) is described. Lead ... Read more...

Latest indexed articles for 'Drug Toxicity'

These are the very latest articles for this heading:

• Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. 29 Nov 2009
• Expanding treatment options for cocaine dependence. 30 Oct 2009
• Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. 6 Oct 2009
• 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103). 6 Oct 2009
• Considerations for reducing the euthanasia procedure in toxicological studies of biopharmaceuticals using non-human primates. 29 Sep 2009
• Side effects of phytoestrogens: a meta-analysis of randomized trials. 29 Sep 2009
• Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. 29 Sep 2009
• Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. 26 Sep 2009
• Can erythropoietin improve developmental outcomes for preterm infants? 19 Sep 2009
• Drug reaction with eosinophilia and systemic symptoms: a cause of human herpesvirus 6-related fulminant myocarditis and hepatitis in immunocompetent patients. 14 Sep 2009
• Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database. 13 Sep 2009
• Health information technology as a tool, not an end: comment on "An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care". 12 Sep 2009
• An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care. 12 Sep 2009
• Medication safety in community pharmacy: a qualitative study of the sociotechnical context. 5 Sep 2009
• Policy statement--recommendations for the prevention and treatment of influenza in children, 2009 -2010. 5 Sep 2009
• Psychotropic drug use during breastfeeding: a review of the evidence. 5 Sep 2009
• How to ascertain drug safety in the context of benefit. Controversies and concerns. 30 Aug 2009
• Observations from the OMERACT Drug Safety Summit, May 2008. 30 Aug 2009
• Safety of using iodized oil in chemoembolization for liver tumors in patients with previous adverse reactions to iodinated contrast media. 30 Aug 2009
• Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Drug Toxicity'

Definition: Manifestations of the adverse effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning for which specific headings are available.

Descriptor UI: D004362

Alternative terms: Drug Toxicity; Drug Toxicities; Toxicities, Drug; Toxicity, Drug; Drug Safety; Safety, Drug; Adverse Drug Reaction; Adverse Drug Reactions; Drug Reaction, Adverse; Drug Reactions, Adverse; Reaction, Adverse Drug; Reactions, Adverse Drug; Adverse Drug Event; Adverse Drug Events; Drug Event, Adverse; Drug Events, Adverse; Event, Adverse Drug; Events, Adverse Drug;

Related Mesh Headings: Drug Interactions; Clinical Trials, Phase IV as Topic;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C21.613.276;

History Note: 98; use explode 1970-97

Technical Notes: note category: do not confuse with TOXICOLOGY, the specialty; general or unspecified; prefer specifics or specific drug with /adv eff /pois or /tox; DF: DRUG TOX